Correction

Prediction of Clinical Response After 1 Year of Infliximab Therapy in Rheumatoid Arthritis Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study*

Takeuchi T, Miyasaka N, Inui T, Yano T, Yoshinari T, Abe T, et al. Prediction of clinical response after 1 year of infliximab

therapy in rheumatoid arthritis based on disease activity at 3 months: posthoc analysis of the RISING study. *J Rheumatol* 2015;42:599-607. In Table 3A, column 1 was incorrectly indented. The corrected table appears here. We regret the error.

*This correction is to the First Release version only, published online February 15, 2015. doi:10.3899/jrheum.140572.C1

Table 3. Independent-associated factors with disease activity, REM/LDA, HAQ score, and functional remission at W54.

Table 3A. Multiple linear regression analysis of SDAI, DAS28-CRP, and HAQ score at W54.

Factors	B	95% CI	β	p
SDAI at W54, $R^2 = 0.3365$				
Constant	5.813	2.502–9.124	0	0.0006
IFX dosage, mg/kg	–0.562	–0.983 – –0.142	–0.123	0.0089
SDAI at W14	0.606	0.508–0.704	0.569	< 0.0001
DAS28-CRP at W54, $R^2 = 0.4114$				
Constant	1.047	0.578–1.517	0	< 0.0001
IFX dosage, mg/kg	–0.081	–0.128 – –0.034	–0.150	0.0007
DAS28-CRP at W14	0.697	0.601–0.793	0.628	< 0.0001
HAQ at W54, $R^2 = 0.3683$				
Constant	–0.091	–0.281–0.099	0	0.3483
IFX dosage, mg/kg	–0.015	–0.035–0.006	–0.063	0.1671
HAQ at W0	0.353	0.253–0.452	0.351	< 0.0001
Disease duration, yrs	0.014	0.006–0.022	0.160	0.0008
SDAI at W14	0.019	0.013–0.024	0.345	< 0.0001
HAQ at W54, $R^2 = 0.3811$				
Constant	–0.401	–0.623 – –0.180	0	0.0004
IFX dosage, mg/kg	–0.015	–0.036–0.005	–0.067	0.1403
HAQ at W0	0.337	0.238–0.437	0.335	< 0.0001
Disease duration, yrs	0.014	0.006–0.022	0.161	0.0006
DAS28-CRP at W14	0.175	0.129–0.221	0.369	< 0.0001

Table 3B. Multiple logistic regression analysis of achievement of REM/LDA and functional remission at W54.

Factors	OR	95% CI	p
REM (SDAI) at W54, $*R^2 = 0.3911$			
IFX dosage, mg/kg	1.127	1.017–1.251	0.0218
Disease duration, yrs	0.947	0.904–0.987	0.0083
SDAI at W14	0.843	0.800–0.882	< 0.0001
LDA (SDAI) at W54, $*R^2 = 0.3087$			
IFX dosage, mg/kg	1.118	1.018–1.232	0.0195
SDAI at W14	0.906	0.880–0.929	< 0.0001
REM (DAS28-CRP) at W54, $*R^2 = 0.3847$			
IFX dosage, mg/kg	1.156	1.050–1.277	0.0031
DAS28-CRP at W14	0.325	0.241–0.424	< 0.0001
LDA (DAS28-CRP) at W54, $*R^2 = 0.3757$			
IFX dosage, mg/kg	1.123	1.023–1.235	0.0143
DAS28-CRP at W14	0.347	0.264–0.445	< 0.0001
Functional remission at W54, $*R^2 = 0.3805$			
IFX dosage, mg/kg	1.065	0.970–1.172	0.1872
HAQ at W0	0.242	0.147–0.386	< 0.0001
SDAI at W14	0.931	0.905–0.955	< 0.0001
Functional remission at W54, $*R^2 = 0.4059$			
IFX dosage, mg/kg	1.078	0.980–1.188	0.1238
Duration of MTX use, yrs	0.880	0.791–0.973	0.0125
HAQ at W0	0.241	0.145–0.387	< 0.0001
DAS28-CRP at W14	0.506	0.395–0.637	< 0.0001

Independent variables were selected using a backward stepwise procedure. Functional remission was defined as HAQ ≤ 0.50 . * Nagelkerke R^2 . REM: clinical remission; LDA: low disease activity; HAQ: Health Assessment Questionnaire; W54: Week 54; SDAI: Simplified Disease Activity Index; DAS28-CRP: 28-joint Disease Activity Score-C-reactive protein; B: nonstandardized coefficients; β : standardized coefficients; R^2 : explained variance; IFX: infliximab; W14: Week 14; W0: Week 0; MTX: methotrexate.